NeOnc Technologies Secures $50mln Partnership, Advances Clinical Trials Platform.

• NeOnc Technologies secures $50M strategic partnership with Quazar Investment • Partnership to launch clinical trials platform in GCC and MENA regions • NeOnc receives $2.5M in NIH funding to advance NEO212 for gliomas and leukemia • Acquisition of AI and 3D tech to expand technology capabilities • Company focuses on CNS cancer therapies in Phase 2 clinical trials

NeOnc Technologies Holdings, Inc. (NASDAQ: NTHI), a biotechnology company focusing on therapies for central nervous system (CNS) cancers, has announced a significant strategic partnership with Quazar Investment. The partnership, valued at $50 million, is set to launch an advanced clinical trials platform in the GCC and MENA regions, expanding NeOnc's global footprint [1].

The agreement with Quazar Investment includes the incorporation of NuroMENA Holdings under the Abu Dhabi Global Market (ADGM). This partnership will facilitate the launch of clinical trials in the GCC and MENA regions, enhancing NeOnc's ability to conduct and expand its research programs in these regions.

Additionally, NeOnc has received $2.5 million in non-dilutive NIH funding to advance NEO212, a bio-conjugated therapy for brain cancer. This funding supports the development of NEO212 for gliomas and leukemia, highlighting the strong scientific validation and external funding support for the company's clinical programs [1].

Further bolstering its technological capabilities, NeOnc has acquired an AI, 3D bioprinting, and quantum modeling IP portfolio from Dr. Ishwar K. Puri. This acquisition will enable NeOnc to leverage advanced technologies in its research and development efforts, positioning the company for innovative breakthroughs in CNS cancer therapies [1].

NeOnc's focus on CNS cancer therapies is evident in its ongoing clinical trials. The company is currently enrolling patients in NEO100-01, an intranasal therapy for malignant gliomas, and NEO212, a bio-conjugated therapy for brain cancer. Both trials are in Phase 2, with top-line data readouts anticipated in early 2026 [1].

The company's financial results for the second quarter of 2025 reflect these strategic initiatives. General and administrative expenses increased to $984K, up from $290K in Q2 2024, primarily due to expanded marketing, rent, travel, and Middle East partnership-related costs. Research and development expenses also increased to $677K, driven by additional trial sites, increased recruitment for NEO212, and the initiation of NEO100-3 [1].

NeOnc's Executive Chairman, Amir Heshmatpour, commented on the company's progress, stating that the partnership with Quazar Investment, the NIH funding, and the acquisition of cutting-edge technology position NeOnc for accelerated growth. He also noted that the company expects to fully enroll both NEO100-01 and NEO212 trials before the end of the third quarter, with FDA readouts anticipated by the end of 2025 and into the beginning of Q1 2026 [1].

References:
[1] https://www.globenewswire.com/news-release/2025/08/19/3135748/0/en/NeOnc-Technologies-Holdings-Reports-Second-Quarter-2025-Results-and-Provides-Operational-Update.html